Myositis

(redirected from inclusion body myositis)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

myositis

[‚mī·ə′sīd·əs]
(medicine)
Inflammation of muscle. Also known as fibromyositis.

Myositis

 

inflammation of skeletal muscles. It usually affects the entire muscular system, that is, it occurs as polymyositis.

Myositis can occur in a variety of diseases and is generally a sign of collagen diseases, that is, systemic diseases of connective tissue. The disease may be acute, subacute, or chronic. Muscle symptoms are often combined with skin disturbances (reddening, edema, induration)—dermatomyositis. A particular form of the disease is parasitic myositis, which results from parasites (Trichinella, Echinococcus, Cysticercus) invading muscles. Another form is myositis ossificans, in which bony tissue forms in muscles. Patients complain of pain in the muscles, muscular weakness, and incoordination; muscular sclerosis and contractures develop in the later stages of the disease. Treatment includes hormone therapy, vitamin therapy, administration of analgesics, and, when indicated, antiparasitic therapy.

REFERENCE

Hausmanowa-Petrusewicz, I. Myshechnye zabolevaniia. Warsaw, 1971. (Translated from Polish.)

V. A. KARLOV

References in periodicals archive ?
Inclusion body myositis, in Engel A, Franzini- Armstrong C (eds): Myology: Basic and Clinical.
Sporadic inclusion body myositis and hereditary inclusion body myositis.
Summary of Bcl-2, Bcl-X, and Bax Immunoreactivity in Inclusion Body Myositis (N = 27) Degene- Regene- Subsar- rating rating Autophagic colemmal Antibody Inflammation Fibers Fibers Vacuoles Staining Bax 26 (96) * 24 (89) 24 (89) 24 (89) 21 (78) Bcl-2 27 (100) 2 (7) 21 (78) 2 (7) 6 (22) Bcl-x 8 (30) 3 (11) 4 (15) 3 (11) 1 (4) * Values are expressed as number positive (%).
Results of the trial in inclusion body myositis will be published in mid 2015.
On August 20, 2013, Novartis AG (Novartis) announced that its BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM) has received a breakthrough therapy designation from the US Food and Drug Administration (FDA).